Alkermes Continues to Execute
Alkermes (NASDAQ: ALKS), a biopharmaceutical company focused on diseases of the central nervous system, released its second-quarter earnings results on Thursday, July 27. The report showed that revenue once again grew at double-digit rates thanks to increased demand for Vivitrol and Aristada. In addition, the company continues to make steady progress at moving its late-stage product candidates one step closer to the finish line.
Image source: Getty images.
Data source: Alkermes. GAAP = generally accepted accounting principles. EPS = earnings per share. NM = not meaningful due to negative figures.
Source: Fool.com
Alkermes plc Stock
?
-0.440%
The stock is one of the favorites of our community with 23 Buy predictions and 1 Sell predictions.
As a result the target price of 46 € shows a slightly positive potential of 7.91% compared to the current price of 42.63 € for Alkermes plc.
